Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TAEST 16001

Next Previous
Drug Profile

TAEST 16001

Alternative Names: Anti-NY-ESO-1 TCR transduced T cells; NY-ESO-1-specific TCR affinity enhancing specific T cell therapy; NY-ESO-1-transduced T-cells - Guangzhou-Pharmaceutical; TAEST-16001; TCR affinity enhancing specific T cell therapy

Latest Information Update: 17 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Guangzhou Institute of Respiratory Disease
  • Developer Axis Therapeutics; Guangdong Xiangxue Precision Medical Technology; Guangzhou Institute of Respiratory Disease; Guangzhou Xiangxue Pharmaceuticals; Sun Yat-Sen University; Xiangxue Life Science Research Center
  • Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Soft tissue sarcoma
  • No development reported Cancer; Non-small cell lung cancer; Osteosarcoma; Solid tumours

Most Recent Events

  • 31 May 2024 Efficacy, safety and pharmacokinetics data from a phase I trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)
  • 28 Jan 2024 No recent reports of development identified for preclinical development in Cancer in USA (IV)
  • 28 Oct 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in China (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top